Evidence map›Paper›PMID 36132011›Full record

ArticleNanoscale advances2022

Hydrophobic soot nanoparticles as a non-cytotoxic motility activator of human spermatozoa.

Karekin D Esmeryan, Ivaylo Rangelov, Todor A Chaushev

Open access · goldAbstract read
In one paragraph

Article in Nanoscale advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Karekin D EsmeryanAcoustoelectronics Laboratory, Georgi Nadjakov Institute of Solid State Physics, Bulgarian Academy of Sciences 72, Tzarigradsko Chaussee Blvd. 1784 Sofia Bulgaria karekin_esmerian@abv.bg +359 2 979 5811.ORCID https://orcid.org/0000-0002-4866-1081
Ivaylo RangelovResearch Department, Medical Center Neovitro OOD 20, Petko Y. Todorov Blvd. 1408 Sofia Bulgaria.ORCID https://orcid.org/0000-0001-5956-5733
Todor A ChaushevResearch Department, Medical Center Neovitro OOD 20, Petko Y. Todorov Blvd. 1408 Sofia Bulgaria.
Bulgarian Academy of Sciences · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sperm cryopreservation is vital in combating the human infertility, but regrettably, the toxicity of cryoprotectants and the occurrence of intracellular icing, osmotic shocks or shrinkage of the cells below a given threshold volume greatly affects the success rate of this technique. Using the virtue of nanotechnologies and depositing water-repellent soot nanoparticles on the inner walls of cryovials may outline new directions in the development of cryobiology, but doubts related to the soot's venomosity question its practical implementability. The scientific content of this article eliminates the existing apprehensions by analyzing the cytotoxicity of three types of rapeseed oil soot, differing in morphology, surface chemistry and zeta potential, towards human spermatozoa. Upon intermittent evaluations of the sperm motility within 270 min of incubation in vials comprising carbon nanoparticles, we reveal that this soot category is non-cytotoxic or at worst, faintly toxic to the gametes provided by twenty individuals. Enhanced progressive sperm motility is observed at ∼50-60% of patients following the soot treatments, which is attributed to electrostatic repulsions and biochemical alterations in the seminal plasma. These fascinating results open new horizons for incorporation of the rapeseed oil soot as a tool for functional preparation and activation of human spermatozoa preceding

Identifiers

PMID36132011
PMCPMC9417005
OpenAlexW4293193068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.